Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MRT-6160 · 1 trial · 1 indication
Frequency of adverse events as assessed by the National Cancer Institute - Common Terminology Criteria for Adverse Events Version 5.0
Frequency of adverse events as assessed by the National Cancer Institute - Common Terminology Criteria for Adverse Events Version 5.0
| Arm | Type | Description |
|---|---|---|
| Single Ascending Dose | EXPERIMENTAL | Single Ascending Dose of either: MRT-6160 or matching placebo |
| Multiple Ascending Dose | EXPERIMENTAL | Multiple Ascending Dose of either: MRT-6160 or matching placebo |
| Name | Type | Description |
|---|---|---|
| MRT-6160 | DRUG | Orally administered tablets or capsules of MRT-6160 |
| Placebo | DRUG | Orally administered tablets or capsules of placebo |
Inclusion Criteria: * Healthy, adult, male or females 19-65 years of age * Non smoker who has not used nicotine and tobacco containing products for at least 3 months prior to start of study * Able to swallow oral medications * Understands the study procedures in the informed consent form (ICF) and ...
MRT-6160 is an investigational small molecule drug developed by Monte Rosa Therapeutics, Inc. It is a Phase 1 clinical-stage candidate that has been studied in healthy adult volunteers. The specific disease indications being pursued for MRT-6160 have not been disclosed.
MRT-6160 targets VAV1, a protein. VAV1 is a guanine nucleotide exchange factor involved in immune cell signaling. By binding to VAV1, MRT-6160 is designed to modulate its activity. This targeted approach distinguishes it from drugs that act on broader pathways.
MRT-6160 is being developed by Monte Rosa Therapeutics, Inc., a biotechnology company. The company trades on the Nasdaq under the ticker symbol GLUE. Monte Rosa specializes in small molecule therapeutics, and MRT-6160 is one of its clinical-stage programs.
MRT-6160 is in Phase 1 clinical development. It has completed a first-in-human study in healthy subjects. As an investigational drug, it has not been approved by the FDA for any indication. Further clinical testing would be required to establish safety and efficacy.
MRT-6160 has been evaluated in a single clinical trial, NCT06597799, titled First-in-human Study of MRT-6160 in Healthy Subjects. This Phase 1 trial enrolled 108 participants in the United States and is now completed. It was randomized, double-blind, and controlled.